Effects of physical activity on side effects from melanoma immunotherapy
Official title: Impact of Physical Activity on Immunotherapy-induced Toxicities in Melanoma Management
Run by University Hospital, Montpellier · NCT06627595 · Data updated 2026-11-12
This study is testing whether staying active can help melanoma patients feel better and experience fewer side effects while receiving immunotherapy.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 160 (estimated) |
| Sponsor | University Hospital, Montpellier Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 2 sites (Montpellier and 1 other locations) |
| Status | Recruiting |
| Started | November 5, 2024 |
| Main results expected | November 5, 2027 |
| Study ends | May 5, 2028 |
| Registry record updated | July 28, 2026 |
| Trial ID | NCT06627595 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older with histologically confirmed melanoma who are about to start immunotherapy.
✕Probably not a fit
Patients with active autoimmune diseases or other medical contraindications to immunotherapy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study investigates how physical activity may influence the immune-related toxicities experienced by melanoma patients undergoing immunotherapy. It focuses on patients who are starting treatment with anti-PD-1 or a combination of anti-PD-1 and anti-CTLA4 therapies. The study aims to understand the potential benefits of adapted physical activity as supportive care in enhancing immune responses and reducing inflammation. By examining the relationship between physical activity and immunotherapy side effects, the study seeks to provide insights into improving patient management.
Why it matters
Potential benefit: If successful, this study could help reduce the side effects of immunotherapy in melanoma patients, improving their quality of life during treatment.
How similar studies have gone: While the role of physical activity in cancer care is gaining attention, this specific approach to managing immunotherapy-induced toxicities in melanoma is relatively novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * age 18 years or above * ECOG performance status inferior or equal to 3 * patient with a melanoma confirmed histologically/pathologically * indication for initiating treatment with anti-PD1 immunotherapy or anti-PD1 + anti-CTLA4 Exclusion Criteria: * patient unable to read and/or write * inability to follow up with the patient during the study period * refusal to participate after a reflection period * medical contraindication to initiating immunotherapy (active autoimmune disease requiring systemic treatment in the past 2 years, active infection, etc.) * not affiliated with a social security system * patient under legal protection, guardianship, or curatorship * person participating in another study that includes an ongoing exclusion period
Where it's running
-
CHU de Montpellier
Montpellier, France Recruiting -
Institut du Cancer de Montpellier (ICM)
Montpellier, France Not yet recruiting
Study contacts
- Study coordinator: Alexandre Maria, MD, PhD
- Email: a-maria@chu-montpellier.fr
- Phone: 00330665849253
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Melanoma treatment with immunotherapy guided by serial ctDNA testing
This trial tests whether regular ctDNA blood tests during treatment can help tailor the plan for patients with advanced melanoma receiving nivolumab and ipilimumab.
-
Non-invasive skin-tape test to detect melanoma using methylation biomarkers
A non-invasive skin-tape test is being tried to see if it can detect melanoma in people who are about to have a biopsy for a suspicious pigmented lesion.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
BL-M08D treatment in melanoma and other solid tumors
A phase Ib/II study tests BL-M08D1 injections in adults with locally advanced or metastatic melanoma and other solid tumors to see if it is safe and helpful.
-
Aggressive lipid lowering in melanoma patients starting immune checkpoint therapy
This trial tests whether lowering cholesterol aggressively can reduce heart artery disease risk in melanoma patients who are just beginning immune checkpoint therapy.
-
Timing of Immunotherapy in Melanoma
This trial tests whether starting standard melanoma immunotherapy earlier in the day (before 10 am) versus later in the day (after 1 pm) makes a difference for patients with unresectable or metastatic melanoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.